EUS-guided Combined Therapy Versus Beta Blocker Therapy in Primary Prophylaxis o GOV II and IGV I

Not Applicable

• Conditions: Gastric Varix; Cirrhosis; GastroIntestinal Bleeding
• Interventions: Procedure: Coils + Cyanoacrylate Group + beta-blocker; Drug: beta blocker therapy

• Registration Number: NCT04075760
• Lead Sponsor: Instituto Ecuatoriano de Enfermedades Digestivas

Brief Summary

The EUS-guided combined therapy of coilingand 2-octyl-cyanoacrylate in patients with gastric varices reduced rebleeding and need for reintervention in comparison to EUS-guided coiling alone.The purpose of this study is to determine the efficacy of the primary prophylaxis of GOV II and IGV I with the EUS combined therapy versus beta blocker therapy in patients GOV II and IGV that have never bleed.

Detailed Description

Gastric variceal bleeding is a severe condition associated with a high mortality. Bleeding from varices bleeding will be defined as the occurrence of hematemesis and/or melena requiring \>2 U of blood or a decrease of 2 gm/dl of hemoglobin if no blood transfusion is given, with the confirmed endocopic visualization of GOV II and IGV I.

The beta blocker therapy is an effective method for the prevention of the first esophageal variceal bleeding; however, the efficacy in preventing first gastric variceal bleeding is controversial.

The investigators aimed to compare the efficacy in preventing the first gastric variceal bleeding in patients with documented GOV II and IGV I.

Study Timeline

• Study Start: 2019-08-01
• Study First Submitted: 2019-08-29
• Study First Submitted QC: 2019-08-30
• Study First Posted: 2019-09-03
• Status Verified: 2019-10
• Last Update Submitted: 2019-10-08
• Last Update Posted: 2019-10-10
• Primary Completion: 2020-08
• Study Completion: 2020-10

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 26

Inclusion Criteria

• Above 18 years old
• Writeen informed consent provided.
• Proven GV (GOV II or IGV I) on esophagogastroduodenoscopy and EUS.
• Gastric varices with high-risk of bleeding (large diameter, high MELD score, presence of portal hypertensive gastropathy)
• Patient preference for EUS-guided therapy.

Exclusion Criteria

• Under 18 years old.
• Refuse to sign written informed consent.
• Pregnancy or nursing.
• Previous treatment of gastric varices.
• Non-cirrhotic portal hypertension
• Concurrent hepato-renal syndrome and/or multi-organ failure.
• Proven malignancy including hepatocellular carcinoma
• Platelet count less than 50,000/ml or International Normalized Rate (INR) >2.
• Severe ascites that increases the distance between gastric or duodenal and gallbladder walls.
• Esophageal stricture.
• Uncontrolled coagulopathy.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
EUS-guided combined therapy	Coils + Cyanoacrylate Group + beta-blocker	Patients with endoscopic and EUS documented GOV II and IGV I will be included. Procedure will be performed under general anesthesia using a linear array therapeuthic echoendoscope, coils and cyanoacrylate will be injected within the feeder vessel under EUS and fluroscopic guidance.
Beta Blocker (Propranolol)	beta blocker therapy	o Beta-blocker (propranolol) will be started at dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose will be increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was \> 90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure \< 90 mm Hg or pulse rate \< 55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication will be attempted if cessation of the medication did not result in improvement of the reported side-effect.

Primary Outcome Measures

Name	Time	Method
Bleeding rate secondary to gastric varices	12 months	Number of patients with melena or hematemesis accompanied by Hemoglobin drop \> 2g/dL
Mortality secondary to gastrointestinal bleeding	12 months	mortality rate

Secondary Outcome Measures

Name	Time	Method
Number of reinterventions	12 months	number of endoscopic or endoscopic ultrasound procedures requiered for the management of gastri varices

Trial Locations

Locations (1)

Instituto Ecuatoriano de Enfermedades Digestivas; 🇪🇨 Guayaquil, Guayas, Ecuador